Inactive Instrument

Spark Therapeutics, Inc.

Equities

US84652J1034

Biotechnology & Medical Research

Spark Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019

May 11, 2019 at 01:37 am IST

Spark Therapeutics, Inc. announced earnings results for the first quarter ended March 31, 2019. For the first quarter, the company announced total revenue was USD 20.771 million compared to USD 15.676 million a year ago. Operating loss was USD 56.846 million compared to USD 48.912 million a year ago. Net loss was USD 54.358 million compared to USD 46.373 million a year ago. Basic loss per share was USD 1.43 compared to USD 1.25 a year ago.

Latest news about Spark Therapeutics, Inc.

Spark Therapeutics Terminates Collaboration Agreement for the Epilepsy Project CG01 with CombiGene AB	15/23/15	CI
Spark Therapeutics, Inc. Enters into Strategic Collaboration with Neurochase Limited for Use of Proprietary Delivery Technology for CNS Disorders	27/23/27	CI
Spark Therapeutics, Inc. Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A	12/22/12	CI
Spark Therapeutics, Inc. Announces Executive Changes, Effective April 1, 2022	23/22/23	CI
Combigene and Spark Therapeutics Plan to Expand the Clinical Development Program to Include the U.S. as Well as Europe	16/21/16	CI
Spark Therapeutics Updated SPK-8011 Data from Phase 1/2 Study Shows Multi-Year, Durable Factor VIII Expression that Significantly Reduced Bleeding in Hemophilia A Patients	18/21/18	CI
CombiGene in Billion-Dollar Deal with Spark Therapeutics	12/21/12	CI
NeuExcell Therapeutics and Spark Therapeutics Announce Research Collaboration Agreement to Develop a Novel Gene Therapy for Huntington's Disease	07/21/07	CI
Spark Therapeutics’ SPK-8011 Suggests Stable and Durable Factor VIII Expression in Largest Phase 1/2 Gene Therapy Study in Hemophilia A to Date	21/21/21	CI
Spark Therapeutics Enters Collaboration with Senti Bio to Bolster Industry-Leading Gene Therapy Research Platform	13/21/13	CI
Spark Therapeutics Appoints Cynthia Pussinen as Chief Technical Officer	25/21/25	CI
Spark Therapeutics Announces Preliminary Data from Phase 1/2 Clinical Trial of SPK-8016 in Hemophilia A at EAHAD 2021 Virtual Congress	05/21/05	CI
Spark Therapeutics Announces First Participant Dosed in Phase 1/2 Study of Investigational Gene Therapy for Late-Onset Pompe Disease	01/21/01	CI
Spark Therapeutics Appoints Michael Retterath as Chief Strategy Officer	16/20/16	CI
Spark Therapeutics, Inc. Appoints Gallia Levy as Chief Medical Officer	10/20/10	CI
Spark Therapeutics Announces Updated Data on SPK-8011 from Phase 1/2 Clinical Trial in Hemophilia A at ISTH 2020 Virtual Congress	12/20/12	CI
Spark Therapeutics, Inc. Demonstrates Role of Ides in Enabling of Gene Therapy in the Presence of Neutralizing Anti-Aav Antibodies Published in Nature Medicine	01/20/01	CI
Spark Therapeutics, Inc.(NasdaqGM:ONCE) dropped from S&P TMI Index	23/19/23	CI
Spark Therapeutics, Inc.(NasdaqGM:ONCE) dropped from S&P Global BMI Index	23/19/23	CI
Spark Therapeutics, Inc.(NasdaqGM:ONCE) dropped from S&P Biotechnology Select Industry Index	23/19/23	CI
Trouble for Boeing, Netflix expands, Amazon toughens up against Fedex…	17/19/17
Spark Therapeutics, Inc. Announces Board Changes	17/19/17	CI
Spark Therapeutics : Roche to complete $4.3 billion Spark deal as regulators give all clear	17/19/17	RE
Spark Therapeutics : Roche to complete $4.3 billion Spark deal as regulators give all clear	17/19/17	RE
Spark Therapeutics, Inc.(NasdaqGM:ONCE) dropped from NASDAQ Composite Index	17/19/17	CI

Chart Spark Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+9.99%	12TCr
REGENERON PHARMACEUTICALS, INC.	+12.01%	11TCr
BIONTECH SE	-3.07%	2.47TCr
ARGENX SE	-0.67%	2.2TCr
GENMAB A/S	-4.45%	1.93TCr
BEIGENE, LTD.	-6.90%	1.76TCr
WUXI APPTEC CO., LTD.	-39.36%	1.73TCr
NEUROCRINE BIOSCIENCES, INC.	+5.82%	1.4TCr
SAREPTA THERAPEUTICS, INC.	+33.05%	1.21TCr

Bio Therapeutic Drugs